. . . . . "escitalopram" . . . "obsessive-compulsive disorder" . . . . . . "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." . . . . . . . "adults" . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" . "PVsL+yEE5Nsi+zVQtMT5N+DrHb4vbNHsbuhBPors+w1mbZIGCe7HmtvoJ3RQm4aUMwU14uisPy1PiKff49zxkKra6uoWE0biyS7WmZGj3Cr7gTPVKo+ebWAVKzy7F4rinpYucZOqDamc811jGl8vbOlH8vR6sqL5rnFYZYT/Glk=" . . "2022-09-16T11:53:46.825298"^^ . . . "2.3.0" .